SymBio Pharmaceuticals Limited
TSE:4582.T
233 (JPY) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 5,589.708 | 10,008.338 | 8,252.582 | 2,987.051 | 2,837.753 | 3,835.53 | 3,444.206 | 2,368.112 | 1,933.241 | 1,955.027 | 1,532.054 | 1,955.178 | 1,882.521 | 1,449.972 | 1,191.127 | 1,630.029 |
| Cost of Revenue
| 1,178.694 | 2,408.434 | 2,452.471 | 2,120.198 | 1,973.002 | 2,662.661 | 2,412.94 | 1,463.919 | 1,350.244 | 1,428.388 | 1,214.061 | 1,362.199 | 1,224.185 | 238.183 | 0 | 0 |
| Gross Profit
| 4,411.014 | 7,599.904 | 5,800.111 | 866.853 | 864.751 | 1,172.869 | 1,031.266 | 904.193 | 582.997 | 526.639 | 317.993 | 592.979 | 658.336 | 1,211.789 | 1,191.127 | 1,630.029 |
| Gross Profit Ratio
| 0.789 | 0.759 | 0.703 | 0.29 | 0.305 | 0.306 | 0.299 | 0.382 | 0.302 | 0.269 | 0.208 | 0.303 | 0.35 | 0.836 | 1 | 1 |
| Reseach & Development Expenses
| 2,638.234 | 2,554.799 | 1,736.126 | 2,266.556 | 2,441.552 | 1,832.746 | 3,017.812 | 1,667.098 | 2,034.714 | 774.103 | 1,052.79 | 1,438.125 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 130 | 122 | 1,336.687 | 524.43 | 5,166.366 | 3,828.941 | 4,978.327 | 3,031.242 | 3,134.659 | 1,829.918 | 1,998.522 | 2,293.253 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 937 | 1,481 | 1,642.559 | 1,301.048 | 733.688 | 405.467 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 2,584.447 | 3,081.479 | 2,979.246 | 3,066.346 | 5,166.366 | 3,828.941 | 4,978.327 | 3,031.242 | 3,134.659 | 1,829.918 | 1,998.522 | 2,293.253 | 0 | 0 | 0 | 0 |
| Other Expenses
| -34.193 | 5,636.278 | 4,784.109 | 5,373.073 | -10.684 | -11.046 | -9.255 | -26.286 | -9.647 | -11.67 | -6.114 | -9.902 | -4.673 | -13.811 | -15.186 | -68.19 |
| Operating Expenses
| 5,222.681 | 5,636.278 | 4,784.109 | 5,373.073 | 5,166.366 | 3,828.941 | 4,978.327 | 3,031.242 | 3,134.659 | 1,829.918 | 1,998.522 | 2,293.253 | 2,725.182 | 1,824.582 | 1,399.155 | 1,497.169 |
| Operating Income
| -811.667 | 1,963.625 | 1,016.001 | -4,506.22 | -4,301.615 | -2,656.072 | -3,947.061 | -2,127.049 | -2,551.662 | -1,303.279 | -1,680.528 | -1,700.273 | -2,066.846 | -612.793 | -208.027 | 132.859 |
| Operating Income Ratio
| -0.145 | 0.196 | 0.123 | -1.509 | -1.516 | -0.692 | -1.146 | -0.898 | -1.32 | -0.667 | -1.097 | -0.87 | -1.098 | -0.423 | -0.175 | 0.082 |
| Total Other Income Expenses Net
| -383.72 | 142.654 | -14.67 | 419.804 | -70.843 | -92.661 | -27.001 | -182.383 | -76.632 | 191.202 | 79.105 | -29.246 | -33.867 | -25.714 | -6.044 | -109.583 |
| Income Before Tax
| -1,195.387 | 2,106.279 | 1,001.331 | -4,086.416 | -4,372.458 | -2,748.733 | -3,974.062 | -2,309.433 | -2,628.295 | -1,112.077 | -1,601.424 | -1,729.52 | -2,100.713 | -638.507 | -214.072 | 23.277 |
| Income Before Tax Ratio
| -0.214 | 0.21 | 0.121 | -1.368 | -1.541 | -0.717 | -1.154 | -0.975 | -1.36 | -0.569 | -1.045 | -0.885 | -1.116 | -0.44 | -0.18 | 0.014 |
| Income Tax Expense
| 767.429 | 927.041 | -1,030.871 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | 2.29 |
| Net Income
| -1,962.817 | 1,179.238 | 2,032.203 | -4,090.216 | -4,376.258 | -2,752.533 | -3,977.862 | -2,313.233 | -2,632.095 | -1,115.877 | -1,605.224 | -1,733.32 | -2,104.513 | -642.307 | -217.872 | 20.987 |
| Net Income Ratio
| -0.351 | 0.118 | 0.246 | -1.369 | -1.542 | -0.718 | -1.155 | -0.977 | -1.361 | -0.571 | -1.048 | -0.887 | -1.118 | -0.443 | -0.183 | 0.013 |
| EPS
| -49.19 | 30.2 | 53.04 | -124.13 | -189.03 | -165.54 | -319.14 | -235.27 | -325.04 | -145.03 | -277.15 | -362.41 | -574.39 | -23,733.77 | -130.11 | 14.58 |
| EPS Diluted
| -49.19 | 29.77 | 52.32 | -124.13 | -189.03 | -165.54 | -319.14 | -235.27 | -325.04 | -145.03 | -277.15 | -362.41 | -574.39 | -23,733.77 | -130.11 | 14.58 |
| EBITDA
| -715.662 | 1,955.317 | 1,109.762 | -4,971.871 | -4,270.463 | -2,621.37 | -3,920.214 | -2,291.153 | -2,606.129 | -1,097.585 | -1,593.23 | -1,720.784 | -2,086.547 | -598.216 | -203.687 | 138.055 |
| EBITDA Ratio
| -0.128 | 0.195 | 0.134 | -1.664 | -1.505 | -0.683 | -1.138 | -0.968 | -1.348 | -0.561 | -1.04 | -0.88 | -1.108 | -0.413 | -0.171 | 0.085 |